Switch theme
Sign up to access all valuation multiples
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
2018
425
LTM Revenue $63.5M
LTM EBITDA n/a
$413M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MeiraGTx has a last 12-month revenue of $63.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, MeiraGTx achieved revenue of $33.3M and an EBITDA of -$122M.
MeiraGTx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MeiraGTx valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $14.0M | $33.3M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$57.1M | -$122M | XXX | XXX | XXX |
| EBITDA Margin | -407% | -366% | XXX | XXX | XXX |
| Net Profit | -$130M | -$84.0M | XXX | XXX | XXX |
| Net Margin | -925% | -252% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, MeiraGTx's stock price is $5.
MeiraGTx has current market cap of $432M, and EV of $413M.
See MeiraGTx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $413M | $432M | XXX | XXX | XXX | XXX | $-1.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, MeiraGTx has market cap of $432M and EV of $413M.
MeiraGTx's trades at 6.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate MeiraGTx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for MeiraGTx and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $413M | XXX | XXX | XXX |
| EV/Revenue | 12.4x | XXX | XXX | XXX |
| EV/EBITDA | -3.4x | XXX | XXX | XXX |
| P/E | -2.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMeiraGTx's NTM/LTM revenue growth is 155%
MeiraGTx's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, MeiraGTx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate MeiraGTx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for MeiraGTx and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 137% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -366% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 114% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -211% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 163% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 359% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 522% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MeiraGTx acquired XXX companies to date.
Last acquisition by MeiraGTx was XXXXXXXX, XXXXX XXXXX XXXXXX . MeiraGTx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was MeiraGTx founded? | MeiraGTx was founded in 2018. |
| Where is MeiraGTx headquartered? | MeiraGTx is headquartered in United States of America. |
| How many employees does MeiraGTx have? | As of today, MeiraGTx has 425 employees. |
| Who is the CEO of MeiraGTx? | MeiraGTx's CEO is Dr. Alexandria Forbes, PhD. |
| Is MeiraGTx publicy listed? | Yes, MeiraGTx is a public company listed on NAS. |
| What is the stock symbol of MeiraGTx? | MeiraGTx trades under MGTX ticker. |
| When did MeiraGTx go public? | MeiraGTx went public in 2018. |
| Who are competitors of MeiraGTx? | Similar companies to MeiraGTx include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of MeiraGTx? | MeiraGTx's current market cap is $432M |
| What is the current revenue of MeiraGTx? | MeiraGTx's last 12-month revenue is $63.5M. |
| What is the current EV/Revenue multiple of MeiraGTx? | Current revenue multiple of MeiraGTx is 6.5x. |
| What is the current revenue growth of MeiraGTx? | MeiraGTx revenue growth between 2023 and 2024 was 137%. |
| Is MeiraGTx profitable? | Yes, MeiraGTx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
